Liraglutide (a long-acting GLP-1 analogue) and semaglutide (a GLP-1 receptor agonist) have been confirmed by clinical controlled trials to slow hepatic steatosis and non-alcoholic steatohepatitis, in addition to affecting insulin release (106, 107). This evidence concerns the gene GCG and Hepatic steatosis.